Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Methyl 4-(?-D-glucopyranosyloxy)-3-hydroxy-5-methoxybenzoate, isolated from Sanguisorba officinalis, inhibits CpG-DNA-induced inflammation

Mohammad Saydur Rahman1, Irshad Ali1, Madeeha Arooj1, Xiang Dong Su2, Seo Young Yang2, Young Ho Kim2, Young-Sang Koh1

1Department of Microbiology and Immunology, School of Medicine and Brain Korea 21 PLUS Program, and Jeju Research Center for Natural Medicine, Jeju National University, Jeju; 2College of Pharmacy, Chungnam National University, Daejon 34134, South Korea.

For correspondence:-  Young-Sang Koh   Email: yskoh7@jejunu.ac.kr   Tel:+82647543851

Accepted: 20 August 2020        Published: 30 September 2020

Citation: Rahman MS, Ali I, Arooj M, Su XD, Yang SY, Kim YH, et al. Methyl 4-(?-D-glucopyranosyloxy)-3-hydroxy-5-methoxybenzoate, isolated from Sanguisorba officinalis, inhibits CpG-DNA-induced inflammation. Trop J Pharm Res 2020; 19(9):1993-1998 doi: 10.4314/tjpr.v19i9.27

© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the anti-inflammatory effect of methyl-4-(β-D-glucopyranosyloxy)-3-hydroxy-5-methoxybenzoate (comp-1) on immune cells.
Methods: Comp-1 was isolated from Sanguisorba officinalis. After treating with comp-1, cell viability and levels of pro-inflammatory cytokines were assessed utilizing MTT assay and ELISA, respectively. Besides, the effects of comp-1 on nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK), and iNOS were determined using western blotting. Moreover, nitric oxide production was assessed using the Griess reagent.
Results: Treatment of dendritic cells (DCs) with CpG DNA upregulated cytokine expression. Comp-1 markedly downregulated the expressions of IL-12 p40, IL-6, and TNF-α, with 50% inhibitory concentrations (IC50) of 1.077 ± 0.04 (p < 0.01), 0.28 ± 0.01 (p < 0.01), and 0.79 ± 0.02 μM (p < 0.01), respectively. Treatment of DCs with CpG DNA upregulated NF-κB and MAPK activation. However, pre-treatment of the cells with Comp-1 suppressed CpG DNA-induced NF-κB and MAPK activation. Moreover, comp-1 exhibited a strong anti-inflammatory effect by inhibiting nitric oxide production and iNOS expression.
Conclusion: These results reveal that comp-1 has significant anti-inflammatory effect on immune cells.

Keywords: Natural compound, Inflammation, Pro-inflammatory cytokine, Toll-like receptor9

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10. 
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2013; 12: 
1,   2,   3,   4,   5,   6. 
2012; 11: 
1,   2,   3,   4,   5,   6. 
2011; 10: 
1,   2,   3,   4,   5,   6. 
2010; 9: 
1,   2,   3,   4,   5,   6. 
2009; 8: 
1,   2,   3,   4,   5,   6. 
2008; 7: 
1,   2,   3,   4. 
2007; 6: 
1,   2,   3,   4. 
2006; 5: 
1,   2. 
2005; 4: 
1,   2. 
2004; 3: 
1. 
2003; 2: 
1,   2. 
2002; 1: 
1,   2. 

News Updates